HARP实时信号 | 通过Getagraph.com最大化利润

购买 107839 min ago

@ $22.46

发出时间: 15 Feb 2024 @ 01:29

回报率: 2.45%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -0.29 %

Live Chart Being Loaded With Signals

Commentary (9 Mar 2024 @ 05:00):

Stats
今日成交量	6.40M
平均成交量	1.13M
市值	865.08M
EPS	$0 ( 2024-03-25 )
下一个收益日期	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.04
ATR14	$0.377 (1.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	395 783	Common Stock
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	10 000	8.000% Series A Redeemable Preferred Stock
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	299 430	Common Stock Warrant (Right to Buy)
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	85 750	Common Stock Warrant (Right to Buy)
2024-03-11	Silvernail Lauren P	Sell	5 000	Common Stock

INSIDER POWER
75.66
Last 96 transactions
Buy: 30 137 007 \| Sell: 5 308 481

音量相关性

長: 0.48 (neutral)

短: 0.40 (neutral)

Signal:(82.718) Neutral

Harpoon Therapeutics Inc 相关性

10 最正相关
APOP	0.898
RMRM	0.892
PAIC	0.857
TDAC	0.851
GAINL	0.843
TLGT	0.841
ISNS	0.821
SVAC	0.813
SPRT	0.808

10 最负相关
MMAC	-0.899
BOCH	-0.892
NETE	-0.858
AMRB	-0.844
SHSP	-0.811
DSPG	-0.808

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Harpoon Therapeutics Inc 相关性 - 货币/商品

-0.16
( neutral )

0.64
( weak )

0.52
( weak )

0.07
( neutral )

0.58
( weak )

0.29
( neutral )

Harpoon Therapeutics Inc 财务报表

Annual	2022
营收:	$31.92M
毛利润:	$28.82M (90.30 %)
EPS:	$-20.24

FY	2022
营收:	$31.92M
毛利润:	$28.82M (90.30 %)
EPS:	$-20.24

FY	2021
营收:	$23.65M
毛利润:	$23.65M (100.00 %)
EPS:	$-3.62

FY	2020
营收:	$17.44M
毛利润:	$17.44M (100.00 %)
EPS:	$-1.990

Financial Reports:

No articles found.

Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.